Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

NCT05107778 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: ASC42 10mg
DRUG: ASC42 15mg
DRUG: ih PEG-IFN α-2a
DRUG: Entecavir
DRUG: Placebo

Sponsor

Ascletis Pharmaceuticals Co., Ltd.